

Special Issue

Advances in the Diagnosis and Management of Age-Related Macular Degeneration: 2nd Edition

Message from the Guest Editor

Age-related macular degeneration (AMD) is a major cause of legal blindness in developed nations. AMD is classified into two types: neovascular and non-neovascular (atrophic) AMD. Recent advances in imaging and therapeutic approaches have improved visual outcomes in eyes with neovascular AMD; that is, anti-vascular endothelial growth factor (VEGF) therapy has become a first-line treatment, supported by multimodal imaging with optical coherence tomography (OCT), fundus photography, fluorescein and indocyanine green angiography, OCT angiography, etc. Photodynamic therapy (PDT) is seldom used at this moment, especially in Western countries; despite this, PDT is still useful in the treatment of polypoidal choroidal vasculopathy and other pachychoroid spectrum diseases, which are predominant phenotypes in Asia. Future candidates of new treatment modalities include drug delivery for bioactive proteins, such as anti-VEGF agents, stem-cell-derived retinal pigment epithelial cell or photoreceptor transplant, gene therapy to produce soluble VEGF receptors, neurotrophic factors (e.g., pigment epithelial growth factor), etc.

Guest Editor

Prof. Dr. Tsutomu Yasukawa

Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan

Deadline for manuscript submissions

28 November 2025



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/217589

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

[jcm](https://jcm.mdpi.com)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).